HighTower Advisors
KIN

HighTower Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

HighTower Advisors’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-62,700
Closed -$312K – 3498
2021
Q1 		$312K Hold
62,700
– – ﹤0.01% 2275
2020
Q4 		$270K Hold
62,700
– – ﹤0.01% 2006
2020
Q3 		$269K Buy
+62,700
New +$262K ﹤0.01% 1895

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

HighTower Advisors's KIN Position: Q2 2021 in Review

HighTower Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 62,700 shares — an estimated $312K sold.

HighTower Advisors first reported a position in KIN in Q3 2020 and held it in 3 quarters. The position peaked at $312K in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • HighTower Advisors reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • HighTower Advisors sold 62,700 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $312K.
  • HighTower Advisors first reported a position in Kindred Biosciences, Inc. in Q3 2020 and held it in 3 quarters.
  • HighTower Advisors's Kindred Biosciences, Inc. position peaked at $312K in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on HighTower Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.